Merck is the latest multinational pharma company to suffer a setback in India, after failing to win an injunction against generic versions of two anti-diabetes drugs.
India’s Supreme Court has rejected pharmaceutical company Novartis’s application to patent an updated version of its leukaemia drug Glivec, agreeing with the Comptroller General that it lacked novelty.
India’s patent office has published final guidelines for examining biotechnology patents, after accepting comments on a draft version published in December.
UK pharmaceutical company AstraZeneca has reached a settlement with Actavis and Egis Pharmaceuticals that delays the release of generic versions of its cholesterol treatment Crestor.
AstraZeneca has signed a five-year licensing deal with Moderna Therapeutics, a US biotechnology company specialising in drugs using RNA therapeutics.
Pharmaceutical companies Bayer, Intendis and Intraserv have filed a patent infringement lawsuit against Glenmark after it applied to market a generic version of rosacea treatment Finacea.
Generic drug maker Mylan has struck a deal with pharma companies Shionogi and Andrx to resolve a patent dispute over their diabetes drug Fortamet.
Janssen Products, a subsidiary of Johnson & Johnson, has sued Indian pharmaceutical company Hetero Drugs for applying to market a generic version of its HIV treatment Prezista.
Recent CJEU judgements on the interpretation of SPC regulations are not clear and have left judges frustrated, said Huw Evans, partner at Norton Rose LLP, at the 1st Annual Life Sciences Law Forum in London.
Day two of the 1st Annual Life Sciences Forum in London saw panellists discuss the European Unitary Patent and the Unified Patent Court.